Page results
-
It’s a clean sweep for our nominees at this year’s RCN Nursing Awards. Congratulations to winners Jo Hargroves, Robert Vicente and Susie Lagrata!
-
The Royal Parks Half Marathon makes a spectacular return this weekend.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.
-
Information on how we ask for your consent to treatment, and Martha's Rule.
-
UCLH continues to achieve excellent results in the National Inpatient Survey. In 2021 patients rated their overall care as 8.5 out of 10 which is the top score in London and the second best in the Shelford Group.
-
The National Day Care Unit provides an opportunity for many people to receive different treatments, tests and procedures without having to stay overnight in the hospital. Some eligible patients who need more than one day of treatment will stay in a hotel near to the hospital.
File results
-
FOI/2023/0038 - Cases where breast milk of a new mother was given to a child who is not her own
-
FOI/2023/0041 - International recruitment
-
FOI/2023/0054 - Local formulary used at the Trust
-
FOI/2023/0058 - Skin cancer pathway management
-
FOI/2023/0063 - Women who have given birth at the Trust aged 50 or above
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0262 - Clinical trial participation